E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types

References

• Global HIV & AIDS statistics — 2020 fact sheet | UNAIDS, Available at https://www.unaids.org/en/resources/fact-sheet (Accessed Feb 18, 2020).
   Google Scholar
• J.M. Lalonde, M.A. Elban, J.R. Courter, A. Sugawara, T. Soeta, N. Madani, A.M. Princiotto, Y.D. Kwon, P.D. Kwong, A. Schön, E. Freire, J. Sodroski, and A.B. Smith III, Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening, Bioorg. Med. Chem. 19 (2011), pp. 91–101. doi:10.1016/j.bmc.2010.11.049.
   PubMed Web of Science ®Google Scholar
• R.W. Shafer and D.A. Vuitton, Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1, Biomed. Pharmacother. 53 (1999), pp. 73–86. doi:10.1016/S0753-3322(99)80063-8.
   PubMed Web of Science ®Google Scholar
• R.J. Lu, J.A. Tucker, T. Zinevitch, O. Kirichenko, V. Konoplev, S. Kuznetsova, S. Sviridov, J. Pickens, S. Tandel, E. Brahmachary, Y. Yang, J. Wang, S. Freel, S. Fisher, A. Sullivan, J. Zhou, S. Stanfield-Oakley, M. Greenberg, D. Bolognesi, B. Bray, B. Koszalka, P. Jeffs, A. Khasanov, Y.A. Ma, C. Jeffries, C. Liu, T. Proskurina, T. Zhu, A. Chucholowski, R. Li, and C. Sexton, Design and synthesis of human immunodeficiency virus entry inhibitors: Sulfonamide as an isostere for the α-ketoamide group, J. Med. Chem. 50 (2007), pp. 6535–6544. doi:10.1021/jm070650e.
   PubMed Web of Science ®Google Scholar
• F. Curreli, Y.D. Kwon, D.S. Belov, R.R. Ramesh, A.V. Kurkin, A. Altieri, P.D. Kwong, and A.K. Debnath, Synthesis, antiviral potency, in vitro ADMET, and X-ray structure of potent CD4 mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120, J. Med. Chem. 60 (2017), pp. 3124–3153. doi:10.1021/acs.jmedchem.7b00179.
   PubMed Web of Science ®Google Scholar
• J.T. Leonard and K. Roy, The HIV entry inhibitors revisited, Curr. Med. Chem. 13 (2006), pp. 911–934. doi:10.2174/092986706776361030.
   PubMed Web of Science ®Google Scholar
• V. Briz, E. Poveda, and V. Soriano, HIV entry inhibitors: Mechanisms of action and resistance pathways, J. Antimirob. Chemother. 57 (2006), pp. 619–627. doi:10.1093/jac/dkl027.
   PubMed Web of Science ®Google Scholar
• P. Acharya, S. Lusvarghi, C.A. Bewley, and P.D. Kwong, HIV-1 gp120 as a therapeutic target: Navigating a moving labyrinth, Expert Opin. Ther. Targets 19 (2015), pp. 765–783. doi:10.1517/14728222.2015.1010513.
   PubMed Web of Science ®Google Scholar
• K. Vermeire and D. Schols, Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor, Expert Opin. Investig. Drugs 14 (2005), pp. 1199–1212. doi:10.1517/13543784.14.10.1199.
   PubMed Web of Science ®Google Scholar
• P.D. Kwong, R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson, Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody, Nature 393 (1998), pp. 648–659. doi:10.1038/31405.
   PubMed Web of Science ®Google Scholar
• N. Madani, A. Schön, A.M. Princiotto, J.M. Lalonde, J.R. Courter, T. Soeta, D. Ng, L. Wang, E.T. Brower, S.H. Xiang, Y.D. Kwon, C.C. Huang, R. Wyatt, P.D. Kwong, E. Freire, A.B. Smith III, and J. Sodroski, Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120, Structure 16 (2008), pp. 1689–1701. doi:10.1016/j.str.2008.09.005.
   PubMed Web of Science ®Google Scholar
• J.R. Courter, N. Madani, J. Sodroski, A. Schön, E. Freire, P.D. Kwong, W.A. Hendrickson, I.M. Chaiken, J.M. Lalonde, and A.B. Smith III, Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: Conversion of a viral entry agonist to an antagonist, Acc. Chem. Res. 47 (2014), pp. 1228–1237. doi:10.1021/ar4002735.
   PubMed Web of Science ®Google Scholar
• A.M. Andrianov, I.A. Kashyn, and A.V. Tuzikov, Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120, J. Mol. Model. 23 (2017), pp. 18. doi:10.1007/s00894-016-3189-4.
   PubMed Web of Science ®Google Scholar
• F. Curreli, D.S. Belov, Y.D. Kwon, R. Ramesh, A.M. Furimsky, K. O’Loughlin, P.C. Byrge, L.V. Iyer, J.C. Mirsalis, A.V. Kurkin, A. Altieri, and A.K. Debnath, Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120, Eur. J. Med. Chem. 154 (2018), pp. 367–391. doi:10.1016/j.ejmech.2018.04.062.
   PubMed Web of Science ®Google Scholar
• W. Li, L. Lu, W. Li, and S. Jiang, Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: A patent review (2010–2015), Expert Opin. Ther. Pat. 27 (2017), pp. 707–719. doi:10.1080/13543776.2017.1281249.
   PubMed Web of Science ®Google Scholar
• E.V. Rullo, M. Ceccarelli, F. Condorelli, A. Facciolà, G. Visalli, F. D’Aleo, I. Paolucci, B. Cacopardo, M.R. Pinzone, M.D. Rosa, G. Nunnari, and G.F. Pellicanò, Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (review), Mol. Med. Rep. 19 (2019), pp. 1987–1995. doi:10.3892/mmr.2019.9840.
   PubMed Web of Science ®Google Scholar
• U. Panwar, I. Chandra, C. Selvaraj, and S.K. Singh, Current computational approaches for the development of anti-HIV inhibitors: An overview, Curr. Pharm. Des. 25 (2019), pp. 3390–3405. doi:10.2174/1381612825666190911160244.
   PubMed Web of Science ®Google Scholar
• Y.D. Kwon, J.M. LaLonde, Y. Yang, M.A. Elban, A. Sugawara, J.R. Courter, D.M. Jones, A.B. Smith III, A.K. Debnath, and P.D. Kwong, Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site, PloS One 9 (2014), pp. e85940. doi:10.1371/journal.pone.0085940.
   PubMed Web of Science ®Google Scholar
• C.B. Wilen, J.C. Tilton, and R.W. Doms, HIV: Cell binding and entry, Cold Spring Harb. Perspect. Med. 2 (2012), pp. a006866. doi:10.1101/cshperspect.a006866.
   PubMed Web of Science ®Google Scholar
• B. Melillo, S. Liang, J. Park, A. Schön, J.R. Courter, J.M. Lalonde, D.J. Wendler, A.M. Princiotto, M.S. Seaman, E. Freire, J. Sodroski, N. Madani, W.A. Hendrickson, and A.B. Smith III, Small-molecule CD4-mimics: Structure-based optimization of HIV-1 entry inhibition, ACS Med. Chem. Lett. 7 (2016), pp. 330–334. doi:10.1021/acsmedchemlett.5b00471.
   PubMed Web of Science ®Google Scholar
• C. Godfrey, M.C. Thigpen, K.W. Crawford, P. Jean-Phillippe, D. Pillay, D. Persaud, D.R. Kuritzkes, M. Wainberg, E. Raizes, and J. Fitzgibbon, Global HIV antiretroviral drug resistance: A perspective and report of a national institute of allergy and infectious diseases consultation, J. Infect Dis. 216 (2017), pp. S798–S800. doi:10.1093/infdis/jix137.
   PubMedGoogle Scholar
• C. Nayak, I. Chandra, and S.K. Singh, An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV-1 protease variants, J. Cell. Biochem. 120 (2019), pp. 9063–9081. doi:10.1002/jcb.28181.
   PubMed Web of Science ®Google Scholar
• B. Lin, X. Sun, S. Su, C. Lv, X. Zhang, L. Lin, R. Wang, J. Fu, and D. Kang, HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China, PloS One 12 (2017), pp. e0181997. doi:10.1371/journal.pone.0181997.
   PubMed Web of Science ®Google Scholar
• L. Menendez-Arias and J.A. Este, HIV-Resistance to viral entry inhibitors, Curr. Pharm. Des. 10 (2005), pp. 1845–1860. doi:10.2174/1381612043384574.
   Web of Science ®Google Scholar
• Q. Guo, H.T. Ho, I. Dicker, L. Fan, N. Zhou, J. Friborg, T. Wang, B.V. McAuliffe, H.G.H. Wang, R.E. Rose, H. Fang, H.T. Scarnati, D.R. Langley, N.A. Meanwell, R. Abraham, R.J. Colonno, and P.F. Lin, Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions, J. Virol. 77 (2003), pp. 10528–10536. doi:10.1128/jvi.77.19.10528-10536.2003.
   PubMed Web of Science ®Google Scholar
• M. Pancera, Y.T. Lai, T. Bylund, A. Druz, S. Narpala, S. O’Dell, A. Schön, R.T. Bailer, G.Y. Chuang, H. Geng, M.K. Louder, R. Rawi, D.I. Soumana, A. Finzi, A. Herschhorn, N. Madani, J. Sodroski, E. Freire, D.R. Langley, J.R. Mascola, A.B. McDermott, and P.D. Kwong, Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529, Nat. Chem. Biol. 13 (2017), pp. 1115–1122. doi:10.1038/nchembio.2460.
   PubMed Web of Science ®Google Scholar
• A. Herschhorn, C. Gu, F. Moraca, X. Ma, M. Farrell, A.B. Smith III, M. Pancera, P.D. Kwong, A. Schön, E. Freire, C. Abrams, S.C. Blanchard, W. Mothes, and J.G. Sodroski, The β20-β21 of gp120 Is a regulatory switch for HIV-1 Env conformational transitions, Nat. Commun. 8 (2017), pp. 1–12. doi:10.1038/s41467-017-01119-w.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2020; Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• K. Sharma, K. Patidar, M.A. Ali, P. Patil, H. Goud, T. Hussain, A. Nayarisseri, and S.K. Singh, Structure-based virtual screening for the identification of high affinity compounds as potent VEGFR2 inhibitors for the treatment of renal cell carcinoma, Curr. Top. Med. Chem. 18 (2018), pp. 2174–2185. doi:10.2174/1568026619666181130142237.
   PubMed Web of Science ®Google Scholar
• S. Abdel-Azeim, Revisiting OPLS-AA force field for the simulation of anionic surfactants in concentrated electrolyte solutions, J. Chem. Theory Comput. 16 (2020), pp. 1136–1145. doi:10.1021/acs.jctc.9b00947.
   PubMed Web of Science ®Google Scholar
• J.H. McAliley and D.A. Bruce, Development of force field parameters for molecular simulation of polylactide, J. Chem. Theory Comput. 7 (2011), pp. 3756–3767. doi:10.1021/ct200251x.
   PubMed Web of Science ®Google Scholar
• G.M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des. 27 (2013), pp. 221–234. doi:10.1007/s10822-013-9644-8.
   PubMed Web of Science ®Google Scholar
• D. Shivakumar, J. Williams, Y. Wu, W. Damm, J. Shelley, and W. Sherman, Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field, J. Chem. Theory Comput. 6 (2010), pp. 1509–1519. doi:10.1021/ct900587b.
   PubMed Web of Science ®Google Scholar
• G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, and W.L. Jorgensen, Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides, J. Phys. Chem. B. 105 (2001), pp. 6474–6487. doi:10.1021/jp003919d.
   Web of Science ®Google Scholar
• S.K. Tripathi, C. Selvaraj, S.K. Singh, and K.K. Reddy, Molecular docking, QPLD, and ADME prediction studies on HIV-1 integrase leads, Med. Chem. Res. 21 (2012), pp. 4239–4251. doi:10.1007/s00044-011-9940-6.
   Google Scholar
• Schrödinger Release 2020-1: Glide, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin, Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem. 47 (2004), pp. 1739–1749. doi:10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release  2020-1: Phase, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• S.L. Dixon, A.M. Smondyrev, and S.N. Rao, PHASE: A novel approach to pharmacophore modeling and 3D database searching, Chem. Biol. Drug Des. 67 (2006), pp. 370–372. doi:10.1111/j.1747-0285.2006.00384.x.
   PubMed Web of Science ®Google Scholar
• K.K. Reddy and S.K. Singh, Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors, Chem. Biol. Interact. 218 (2014), pp. 71–81. doi:10.1016/j.cbi.2014.04.011.
   Google Scholar
• H. Kubinyi, Chemical similarity and biological activities, J. Braz. Chem. Soc. 13 (2002), pp. 717–726. doi:10.1590/S0103-50532002000600002.
   Web of Science ®Google Scholar
• K. Loving, N.K. Salam, and W. Sherman, Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation, J. Comput. Aided Mol. Des. 23 (2009), pp. 541–554. doi:10.1007/s10822-009-9268-1.
   PubMed Web of Science ®Google Scholar
• I. Chandra, A.K. Behera, and S.S. Cherian, Identification of potential inhibitors against the human influenza A virus targeting the CPSF30 and RNA binding domains of the NS1 protein: An e-pharmacophore approach, Indian J. Pharm. Educ. Res. 51 (2017), pp. 25–33. doi:10.5530/ijper.51.1.5.
   Web of Science ®Google Scholar
• P.J. Therese, D. Manvar, S. Kondepudi, M.B. Battu, D. Sriram, A. Basu, P. Yogeeswari, and N. Kaushik-Basu, Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors, J. Chem. Inf. Model. 54 (2014), pp. 539–552. doi:10.1021/ci400644r.
   PubMed Web of Science ®Google Scholar
• S.V. Prabhu and S.K. Singh, Energetically optimized pharmacophore modeling to identify dual negative allosteric modulators against group I mGluRs in neurodegenerative diseases, J. Biomol. Struct. Dyn. 38 (2020), pp. 2326–2337. doi:10.1080/07391102.2019.1640794.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: LigPrep, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• I.J. Chen and N. Foloppe, Drug-like bioactive structures and conformational coverage with the ligPrep/confgen suite: Comparison to programs MOE and catalyst, J. Chem. Inf. Model 50 (2010), pp. 822–839. doi:10.1021/ci100026x.
   PubMed Web of Science ®Google Scholar
• P. Daisy, P. Vijayalakshmi, C. Selvaraj, S.K. Singh, and K. Saipriya, Targeting multidrug resistant Mycobacterium tuberculosis HtrA2 with identical chemical entities of fluoroquinolones, Indian J. Pharm. Sci. 74 (2012), pp. 217–222. doi:10.4103/0250-474X.106063.
   PubMed Web of Science ®Google Scholar
• J.F. Truchon and C.I. Bayly, Evaluating virtual screening methods: Good and bad metrics for the “early recognition” problem, J. Chem. Inf. Model. 47 (2007), pp. 488–508. doi:10.1021/ci600426e.
   PubMed Web of Science ®Google Scholar
• H. Patel and A. Kukol, Evaluation of a novel virtual screening strategy using receptor decoy binding sites, J. Negat. Results Biomed. 15 (2016), pp. 1–5. doi:10.1186/s12952-016-0058-8.
   PubMedGoogle Scholar
• K.K. Reddy, S.K. Singh, S.K. Tripathi, and C. Selvaraj, Identification of potential HIV-1 integrase strand transfer inhibitors: In silico virtual screening and QM/MM docking studies, SAR QSAR Environ. Res. 24 (2013), pp. 581–595. doi:10.1080/1062936X.2013.772919.
   PubMed Web of Science ®Google Scholar
• D. Pradiba, M. Aarthy, V. Shunmugapriya, S.K. Singh, and M. Vasanthi, Structural insights into the binding mode of flavonols with the active site of matrix metalloproteinase-9 through molecular docking and molecular dynamic simulations studies, J. Biomol. Struct. Dyn. 36 (2018), pp. 3718–3739. doi:10.1080/07391102.2017.1397058.
   PubMed Web of Science ®Google Scholar
• V. Suryanarayanan and S.K. Singh, Assessment of dual inhibition property of newly discovered inhibitors against PCAF and GCN5 through in silico screening, molecular dynamics simulation and DFT approach, J. Recept. Signal Transduct. Res. 35 (2015), pp. 370–380. doi:10.3109/10799893.2014.956756.
   PubMed Web of Science ®Google Scholar
• W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, and R. Farid, Novel procedure for modeling ligand/receptor induced fit effects, J. Med. Chem. 49 (2005), pp. 534–553. doi:10.1021/jm050540c.
   Web of Science ®Google Scholar
• L. Delgado-Soler, J. Ariñez-Soriano, J.M. Granadino-Roldán, and J. Rubio-Martinez, Predicting binding energies of CDK6 inhibitors in the hit-to-lead process, Theor. Chem. Acc. 128 (2011), pp. 807–823. doi:10.1007/s00214-010-0857-9.
   Web of Science ®Google Scholar
• M. Aarthy and S.K. Singh, Discovery of potent inhibitors for the inhibition of dengue envelope protein: An in silico approach, Curr. Top. Med. Chem. 18 (2018), pp. 1585–1602. doi:10.2174/1568026618666181025100736.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: Prime, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• R. Kumar, M. Son, R. Bavi, Y. Lee, C. Park, V. Arulalapperumal, G.P. Cao, H.H. Kim, J.K. Suh, Y.S. Kim, and Y.J. Kwon, Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling, Acta Pharmacol. Sin. 36 (2015), pp. 998–1012. doi:10.1038/aps.2015.17.
   PubMed Web of Science ®Google Scholar
• C. Selvaraj, J. Sivakamavalli, B. Vaseeharan, P. Singh, and S.K. Singh, Structural elucidation of SrtA enzyme in Enterococcus faecalis: An emphasis on screening of potential inhibitors against the biofilm formation, Mol. Biosyst. 10 (2014), pp. 1775–1789. doi:10.1039/C3MB70613C.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: QikProp, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• S. Sharda, P. Sarmandal, S. Cherukommu, K. Dindhoria, M. Yadav, S. Bandaru, A. Sharma, A. Sakhi, T. Vyas, T. Hussain, A. Nayarisseri, and S.K. Singh, A virtual screening approach for the identification of high affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia, Curr. Top Med. Chem. 17 (2017), pp. 2989–2996. doi:10.2174/1568026617666170821124512.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2020. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2020.
   Google Scholar
• G.K. Veeramachaneni, K.K. Raj, L.M. Chalasani, J.S. Bondili, and V.R. Talluri, High-throughput virtual screening with e-pharmacophore and molecular simulations study in the designing of pancreatic lipase inhibitors, Drug Des. Devel. Ther. 9 (2015), pp. 4397–4412. doi:10.2147/DDDT.S84052.
   PubMed Web of Science ®Google Scholar
• A. Grover, S.P. Katiyar, S.K. Singh, V.K. Dubey, and D. Sundar, A leishmaniasis study: Structure-based screening and molecular dynamics mechanistic analysis for discovering potent inhibitors of spermidine synthase, BBA-Proteins Proteom 1824 (2012), pp. 1476–1483. doi:10.1016/j.bbapap.2012.05.016.
   PubMed Web of Science ®Google Scholar
• B. Shanmuganathan, V. Suryanarayanan, S. Sathya, M. Narenkumar, S.K. Singh, K. Ruckmani, and K.P. Devi, Anti-amyloidogenic and anti-apoptotic effect of α-bisabolol against Aβ induced neurotoxicity in PC12 cells, Eur. J. Med. Chem. 143 (2018), pp. 1196–1207. doi:10.1016/j.ejmech.2017.10.017.
   PubMed Web of Science ®Google Scholar
• S. Bandaru, M. Alvala, A. Nayarisseri, S. Sharda, H. Goud, H.P. Mundluru, and S.K. Singh, Molecular dynamics simulations reveal suboptimal binding of Salbutamol in T164I variant of β2 adrenergic receptor, PLoS One 12 (2017), pp. e0186666. doi:10.1371/journal.pone.0186666.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2020-1: Jaguar, Schrödinger, LLC, New York, NY, 2020.
   Google Scholar
• U. Panwar and S.K. Singh, Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75), J. Biomol. Struct. Dyn. 36 (2018), pp. 3199–3217. doi:10.1080/07391102.2017.1384400.
   Google Scholar
• D.R. Motati, D. Uredi, and E.B. Watkins, The discovery and development of oxalamide and pyrrole small molecule inhibitors of gp120 and HIV entry - A review, Curr. Top. Med. Chem. 19 (2019), pp. 1650–1675. doi:10.2174/1568026619666190717163959.
   PubMed Web of Science ®Google Scholar
• A.M. Andrianov, G.I. Nikolaev, Y.V. Kornoushenko, W. Xu, S. Jiang, and A.V. Tuzikov, In silico identification of novel aromatic compounds as potential HIV-1 entry inhibitors mimicking cellular receptor CD4, Viruses 11 (2019), pp. 746. doi:10.3390/v11080746.
   Web of Science ®Google Scholar
• D.J. Castillo-Pazos, A. Romo-Mancillas, and J. Barroso-Flores, Piperazine-based HIV-1 entry inhibitors: Massive in silico library design and screening for gp120 attachment inhibitors, bioRxiv (2018), pp. 330142. doi:10.1101/330142.
   Google Scholar
• R. Patil, S. Das, A. Stanley, L. Yadav, A. Sudhakar, and A.K. Varma, Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing, PloS One 5 (2010), pp. e12029. doi:10.1371/journal.pone.0012029.
   PubMed Web of Science ®Google Scholar
• H. Sun, L. Duan, F. Chen, H. Liu, Z. Wang, P. Pan, F. Zhu, J.Z.H. Zhang, and T. Hou, Assessing the performance of MM/PBSA and MM/GBSA methods. 7. entropy effects on the performance of end-point binding free energy calculation approaches, Phys. Chem. Chem. Phys. 20 (2018), pp. 14450–14460. doi:10.1039/C7CP07623A.
   PubMed Web of Science ®Google Scholar
• X. Du, Y. Li, Y.L. Xia, S.M. Ai, J. Liang, P. Sang, X.L. Ji, and S.Q. Liu, Insights into protein–ligand interactions: Mechanisms, models, and methods, Int. J. Mol. Sci. 17 (2016), pp. 144. doi:10.3390/ijms17020144.
   PubMed Web of Science ®Google Scholar
• K. Ogata, M. Hatakeyama, and S. Nakamura, Effect of atomic charges on octanol–water partition coefficient using alchemical free energy calculation, Molecules 23 (2018), pp. 425. doi:10.3390/molecules23020425.
   Web of Science ®Google Scholar
• R.H. Henchman, K. Tai, T. Shen, and J.A. McCammon, Properties of water molecules in the active site gorge of acetylcholinesterase from computer simulation, Biophys. J. 82 (2002), pp. 2671–2682. doi:10.1016/S0006-3495(02)75609-9.
   PubMed Web of Science ®Google Scholar
• B. Mathew, S. Dev, M. Joy, G.E. Mathew, A. Marathakam, and G.K. Krishnan, Refining the structural features of chromones as selective MAO‐B inhibitors: Exploration of combined pharmacophore‐based 3D‐QSAR and quantum chemical studies, ChemistrySelect 2 (2017), pp. 11645–11652. doi:10.1002/slct.201701213.
   Web of Science ®Google Scholar
• S.K. Singh, N. Dessalew, and P.V. Bharatam, 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors, Med. Chem. 3 (2007), pp. 75–84. doi:10.2174/157340607779317517.
   PubMed Web of Science ®Google Scholar
• B. Mathew, A.A. Adeniyi, S. Dev, M. Joy, G. Ucar, G.E. Mathew, A. Singh-Pillay, and M.E.S. Soliman, Pharmacophore-based 3D-QSAR analysis of thienyl chalcones as a new class of human MAO-B inhibitors: Investigation of combined quantum chemical and molecular dynamics approach, J. Phys. Chem. B 121 (2017), pp. 1186–1203. doi:10.1021/acs.jpcb.6b09451.
   PubMed Web of Science ®Google Scholar
• P.K. Weiner, R. Langridge, J.M. Blaney, R. Schaefer, and P.A. Kollman, Electrostatic potential molecular surfaces, Proc Natl. Acad. Sci. USA 79 (1982), pp. 3754–3758. doi:10.1073/pnas.79.12.3754.
   PubMed Web of Science ®Google Scholar
• S.K. Tripathi and S.K. Singh, Insights into the structural basis of 3, 5-diaminoindazoles as CDK2 inhibitors: Prediction of binding modes and potency by QM–MM interaction, MESP and MD simulation, Mol. Biosyst. 10 (2014), pp. 2189–2201. doi:10.1039/C4MB00077C.
   PubMedGoogle Scholar